Markets
Degenerate
@wsb
Bought RXRX
Shares
up 0.46%
At 5.38, Exited 5.41
With the FDA's announcement to phase out animal testing in favor of AI-based models, I believe RXRX is set to see significant growth. The demand for A...
Read
More
Thesis
With the FDA's announcement to phase out animal testing in favor of AI-based models, I believe RXRX is set to see significant growth. The demand for AI drug discovery will lead to increased partnerships and revenue opportunities, making this stock a strong buy as it moves closer to acquisition discussions with big pharma.
Go back
Tendies
@tendies
Bought RXRX
Shares
down -21.62%
At 5.07, Exited 3.97
I'm really bullish on Recursion Pharmaceuticals. Their AI-driven platform in drug discovery is a game changer, and with major partnerships and potenti...
Read
More
Thesis
I'm really bullish on Recursion Pharmaceuticals. Their AI-driven platform in drug discovery is a game changer, and with major partnerships and potential revenue streams lined up, I believe this stock could easily reach $20-$30 in the coming years. The hype around their unique TechBio approach is just beginning.
Go back
Degenerate
@wsb
Bought RXRX
Shares
down -18.18%
At 11.0, Exited 9.0
I think Recursion is on the verge of a significant breakthrough, especially with the backing from NVIDIA and Novo Nordisk. The momentum from the recen...
Read
More
Thesis
I think Recursion is on the verge of a significant breakthrough, especially with the backing from NVIDIA and Novo Nordisk. The momentum from the recent rally and potential collaborations could lead to substantial gains in the near future. I'm positioning myself for a swing trade on this one.
Go back
Posted
153d ago
476%
Swung
•
Bullish
•
Exited
OG
@ogpennyd...
SYMB
Locked Data
some %
entered at Buy it
This
is a test thesis that is a placeholder for paid trades. Once you unlock this trade, you will
see
the actual thesis. Thank you, dont try to cheat!
Trade is closed already
Thesis
Healthcare ai
Go back
Scalp
@scalpgan...
Bought RXRX
Shares
up 10.77%
At 6.92, Exited 7.66
I just made a solid trade on RXRX after spotting some positive momentum and the price moving in an ascending triangle pattern. I think it’s poised for...
Read
More
Thesis
I just made a solid trade on RXRX after spotting some positive momentum and the price moving in an ascending triangle pattern. I think it’s poised for a nice upward move in the coming weeks, especially with increasing bullish volume. I'm feeling confident about this one!
Go back
Degenerate
@wsb
Bought RXRX
Shares
down -13.8%
At 8.26, Exited 7.12
I'm super bullish on RXRX right now. With their recent positive clinical data for REC-617 and the potential breakthroughs in cancer treatment, it's cl...
Read
More
Thesis
I'm super bullish on RXRX right now. With their recent positive clinical data for REC-617 and the potential breakthroughs in cancer treatment, it's clear the company is on the cutting edge. This feels like a prime opportunity to ride this stock up as momentum builds.
Go back
Degenerate
@wsb
Bought RXRX
Calls
down -65.24%
At 0.37, Now 0.13
Contract:
7 Strike Call for
Nov 29, 24
I'm feeling bullish on RXRX due to the low-cost options and the upcoming catalyst in December. The potential for a squeeze and AI medicine play makes ...
Read
More
Thesis
I'm feeling bullish on RXRX due to the low-cost options and the upcoming catalyst in December. The potential for a squeeze and AI medicine play makes these January $7 calls look like a solid bet for gains.
Go back
Degenerate
@wsb
Bought RXRX
Shares
up 3.94%
At 6.34, Exited 6.59
I believe Recursion Pharmaceuticals is on the verge of a major breakout, especially with their upcoming seminar on December 9th for key drug readouts....
Read
More
Thesis
I believe Recursion Pharmaceuticals is on the verge of a major breakout, especially with their upcoming seminar on December 9th for key drug readouts. With significant backing and data, I'm loading up on shares, seeing immense long-term potential in AI-driven drug development.
Go back
The
@themarke...
Bought RXRX
Shares
up 5.63%
At 6.04, Exited 6.38
Just threw some money into RXRX at its 52-week all-time low. I believe this AI biotech stock has potential for growth, especially if the AI wave conti...
Read
More
Thesis
Just threw some money into RXRX at its 52-week all-time low. I believe this AI biotech stock has potential for growth, especially if the AI wave continues. It seems like a solid investment opportunity for the next few months.
Go back
TLAMB91
@tlamb91
Bought RXRX
Shares
down -31.08%
At 6.29, Now 4.33
being loaded again in this prior gap fill support area
Thesis
being loaded again in this prior gap fill support area
Go back
Degenerate
@wsb
Bought RXRX
Shares
up 1.21%
At 6.6, Exited 6.68
I just bought RXRX at $6.70 because I see a lot of institutional buying, including Blackrock and State Street. The short interest is significant, and ...
Read
More
Thesis
I just bought RXRX at $6.70 because I see a lot of institutional buying, including Blackrock and State Street. The short interest is significant, and I believe the current valuation makes it a great medium-term investment opportunity.
Go back
Tendies
@tendies
Bought RXRX
Shares
down -2.07%
At 6.75, Exited 6.61
I believe RXRX has significant potential due to Nvidia's substantial investment, which could drive the stock price up in the coming months. Despite th...
Read
More
Thesis
I believe RXRX has significant potential due to Nvidia's substantial investment, which could drive the stock price up in the coming months. Despite the bad financials, the backing from a tech giant like Nvidia makes me think there's an opportunity for a solid swing trade.
Go back
The
@themarke...
Bought RXRX
Shares
down -8.52%
At 6.75, Exited 6.17
Recursion Pharmaceuticals has a strong pipeline and strategic AI-driven acquisitions, setting it up for significant growth. The company’s robust finan...
Read
More
Thesis
Recursion Pharmaceuticals has a strong pipeline and strategic AI-driven acquisitions, setting it up for significant growth. The company’s robust financial position and advanced drug candidates make it a compelling long-term investment opportunity.
Go back
The
@themarke...
Bought RXRX
Shares
up 2.37%
At 6.75, Exited 6.91
Recursion Pharmaceuticals is poised for significant growth with its robust drug pipeline, strong financial position, and the strategic acquisition of ...
Read
More
Thesis
Recursion Pharmaceuticals is poised for significant growth with its robust drug pipeline, strong financial position, and the strategic acquisition of Exscientia. The potential upside from its innovative R&D and AI-driven drug discovery makes RXRX a promising long-term buy.
Go back
Point72
@point72-...
Bought RXRX
Shares
down -7.86%
At 7.16, Exited 7.5
Trims & Adds
[] Lost $1.1M on the trade
[-] 1.0y ago
All out @
7.50
[-] 1.3y ago
Trimmed 1.1M shares @
9.37
[+] 1.5y ago
Added 1.3M shares @
9.87
[+] 1.8y ago
Initial 137.5K shares @
7.16
Thesis
Go back
